8-K: Progyny Reports Record Q1 2025 Revenue, Raises Full Year Guidance

Progyny announces strong Q1 2025 results with record revenue of $324.0 million, a 16.5% increase year-over-year, and raises its full-year guidance.

Summary

• Progyny, Inc. announced its financial results for the first quarter of 2025, reporting record revenue of $324.0 million, a 16.5% increase compared to Q1 2024.
• The company's gross profit increased by 21% to $75.8 million, with a gross margin of 23.4%.
• Net income was $15.1 million, or $0.17 per diluted share, while Adjusted EBITDA reached $57.8 million, a 15% increase.
• Progyny had 532 fertility and family building clients as of March 31, 2025, compared to 451 in the previous year.
• The company is raising its full-year 2025 revenue guidance to $1.185 billion to $1.235 billion, reflecting growth of 1.5% to 5.8%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and raised guidance, indicating a favorable sentiment.

Positives

• Record revenue of $324.0 million in Q1 2025, representing a 16.5% increase year-over-year.
• Gross profit increased by 21% to $75.8 million.
• Adjusted EBITDA increased by 15% to $57.8 million.
• The company's client base grew to 532 fertility and family building clients.
• Full-year revenue guidance raised to $1.185 billion to $1.235 billion.

Negatives

• Net income decreased slightly to $15.1 million from $16.9 million in Q1 2024, primarily due to a higher provision for income taxes.
• Adjusted EBITDA margin decreased slightly to 17.8% from 18.1% in Q1 2024.
• A large client did not renew its services agreement for 2025, though there is an extended transition period over the first half of 2025.

Risks

• Ongoing macroeconomic uncertainty could impact the company's performance.
• The loss of a large client account could affect future revenue.
• Variability in member engagement could impact financial results.
• The company faces competition in the market for women's health and family building solutions.

Future Outlook

Progyny is providing full-year 2025 revenue guidance of $1.185 billion to $1.235 billion and second quarter 2025 revenue guidance of $310.0 million to $325.0 million.

Management Comments

• Pete Anevski, CEO, stated that the company is pleased with the strong start to the year and the progress made with investments to expand the platform.
• Mark Livingston, CFO, noted that the first quarter results reflect double-digit revenue growth, increased gross margin, and significant cash flow.

Industry Context

Progyny's focus on women's health and family building solutions aligns with the growing trend of employers prioritizing these benefits to attract and retain talent.

Comparison to Industry Standards

• Progyny's growth rate of 16.5% in Q1 2025 is strong compared to other companies in the benefits administration and healthcare technology sectors.
• Companies like Accolade and Teladoc Health, which also operate in the broader healthcare space, have experienced varying growth rates, making Progyny's performance noteworthy.
• Progyny's focus on fertility benefits gives it a unique position compared to broader health benefits providers like UnitedHealth Group or Anthem.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may benefit from the company's continued growth and investments in its platform.
• Clients can expect continued access to Progyny's comprehensive fertility and family building solutions.

Next Steps

• Progyny will host a conference call on May 8, 2025, to discuss its financial results.
• The company will continue to focus on expanding its platform and integrating recent acquisitions.
• Progyny will monitor the macroeconomic environment and its impact on member engagement.

Key Dates

Keywords

Progyny, fertility benefits, family building, women's health, financial results, revenue, EBITDA, guidance